BR0114424A - Derivados de 5-amidino-2-hidróxi benzeno sulfonamida, composições farmacêuticas contendo os mesmos e intermediários para a sua preparação - Google Patents

Derivados de 5-amidino-2-hidróxi benzeno sulfonamida, composições farmacêuticas contendo os mesmos e intermediários para a sua preparação

Info

Publication number
BR0114424A
BR0114424A BR0114424-3A BR0114424A BR0114424A BR 0114424 A BR0114424 A BR 0114424A BR 0114424 A BR0114424 A BR 0114424A BR 0114424 A BR0114424 A BR 0114424A
Authority
BR
Brazil
Prior art keywords
group
optionally substituted
lower alkyl
amidino
hydrogen atom
Prior art date
Application number
BR0114424-3A
Other languages
English (en)
Inventor
Kosuke Okazaki
Masahiko Uchida
Harunobu Mukaiyama
Hiroaki Kobayashi
Yuichiro Kai
Hideki Takeuchi
Kenji Yokoyama
Yoshihiro Terao
Yuji Hoyano
Hiroaki Shiohara
Norihiko Kikuchi
Original Assignee
Kissei Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kissei Pharmaceutical filed Critical Kissei Pharmaceutical
Publication of BR0114424A publication Critical patent/BR0114424A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"DERIVADOS DE 5-AMIDINO-2-HIDRóXI BENZENO SULFONAMIDA, COMPOSIçõES FARMACêUTICAS CONTENDO OS MESMOS E INTERMEDIáRIOS PARA A SUA PREPARAçãO". Derivados de 5-amidino-2-hidróxi-benzeno-sulfonamida da fórmula geral (I) ou seus sais aceitáveis do ponto de vista farmacêutico, apresentando uma atividade inibidora potente e seletiva contra o fator X de coagulação sanguínea ativado e sendo útil em forma de medicamentos preventivos e terapêuticos para doenças cujo aparecimento é relacionado com o fator X de coagulação sang³ínea ativado; composições farmacêuticas contendo os mesmos; o seu emprego em medicamentos; e intermediários para a sua preparação: (I) em que R^ 1^ é hidrogênio ou alquila inferior opcionalmente substituído; R^ 2^ é di (alquil inferior) amino, alquila inferior, ciclo-alquila, arila opcionalmente substituído, hetero ciclo-alquila opcionalmente substituído, ou um grupamento aromático heterociclico opcionalmente substituído; T é oxigênio, enxofre, sulfonila, ou semelhante; Q é hidrogênio ou alquila inferior opcionalmente substituído; e Z é hidrogênio, hidroxila ou semelhante.
BR0114424-3A 2000-10-04 2001-10-02 Derivados de 5-amidino-2-hidróxi benzeno sulfonamida, composições farmacêuticas contendo os mesmos e intermediários para a sua preparação BR0114424A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000305569 2000-10-04
JP2001191486 2001-06-25
PCT/JP2001/008670 WO2002028827A1 (fr) 2000-10-04 2001-10-02 Derives de 5-amidino-2-hydroxybenzenesulfonamide, compositions pharmaceutiques les contenant et leurs intermediaires de preparation

Publications (1)

Publication Number Publication Date
BR0114424A true BR0114424A (pt) 2004-02-17

Family

ID=26601572

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0114424-3A BR0114424A (pt) 2000-10-04 2001-10-02 Derivados de 5-amidino-2-hidróxi benzeno sulfonamida, composições farmacêuticas contendo os mesmos e intermediários para a sua preparação

Country Status (18)

Country Link
US (3) US7208524B2 (pt)
EP (1) EP1331221B1 (pt)
JP (1) JP3967679B2 (pt)
KR (1) KR100625023B1 (pt)
CN (1) CN100439329C (pt)
AT (1) ATE420853T1 (pt)
AU (2) AU9233101A (pt)
BR (1) BR0114424A (pt)
CA (1) CA2423631C (pt)
DE (1) DE60137442D1 (pt)
ES (1) ES2319504T3 (pt)
HK (1) HK1061674A1 (pt)
MX (1) MXPA03002975A (pt)
NZ (1) NZ525114A (pt)
PL (1) PL206094B1 (pt)
RU (1) RU2273633C9 (pt)
TW (1) TWI303628B (pt)
WO (1) WO2002028827A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI303628B (en) 2000-10-04 2008-12-01 Kissei Pharmaceutical 5-amidino-2-hydroxybenienesulfonamide derivatives, pharmaceutical compositions containing the same and intermediates for their preparation
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7705120B2 (en) 2001-06-21 2010-04-27 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
CA2457482A1 (en) 2001-08-09 2003-02-27 Kissei Pharmaceutical Co., Ltd. 5-amidino-n-(2-aminophenethyl)-2-hydroxybenzenesulfonamide derivative, medicinal composition containing the same, and intermediate therefor
BR0308426A (pt) * 2002-03-15 2005-01-18 Kissei Pharmaceutical Cristais de derivado de 5-hidroxicarbamimidoil-2-hidroxibenzenosulfonami da
EP1491187A4 (en) * 2002-03-22 2008-04-16 Kissei Pharmaceutical PREVENTIVE OR THERAPEUTIC AGENT FOR RENAL DISEASES
WO2004050611A1 (ja) * 2002-12-02 2004-06-17 Kissei Pharmaceutical Co., Ltd. 新規なビフェニルオキシ酢酸誘導体ならびにその製造方法および使用方法
EP1679067A4 (en) * 2003-09-19 2010-04-07 Kissei Pharmaceutical COMBINED MEDICINES
JP4900238B2 (ja) 2005-02-02 2012-03-21 味の素株式会社 新規ベンズアミジン化合物
JPWO2010005087A1 (ja) 2008-07-11 2012-01-05 味の素株式会社 アミジン誘導体
KR101045318B1 (ko) * 2011-03-17 2011-06-29 (주)삼오포레스 콘크리트 자갈의 다공성 집합성형체 시공방법
CN106588847B (zh) * 2016-12-09 2019-08-13 上海中医药大学 二氢香豆素类衍生物及其制备方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3700773A (en) * 1969-06-25 1972-10-24 Merck & Co Inc Substituted phenylsulfamyl salicyclic acids and derivatives thereof in the treatment of inflammation
SE9602646D0 (sv) * 1996-07-04 1996-07-04 Astra Ab Pharmaceutically-useful compounds
US6506936B1 (en) * 1999-02-25 2003-01-14 Fibrogen, Inc. N-substituted arylsulfonylamino hydroxamic acids useful as inhibitors of c-proteinase and for treating or preventing disorders related to unregulated collagen production
WO2000059876A1 (fr) * 1999-03-31 2000-10-12 Kissei Pharmaceutical Co., Ltd. Derives de 3-amidinobenzenesulfonamide, compositions medicales qui les contiennent, et produits intermediaires pour leur elaboration
TWI303628B (en) 2000-10-04 2008-12-01 Kissei Pharmaceutical 5-amidino-2-hydroxybenienesulfonamide derivatives, pharmaceutical compositions containing the same and intermediates for their preparation
EP1491187A4 (en) * 2002-03-22 2008-04-16 Kissei Pharmaceutical PREVENTIVE OR THERAPEUTIC AGENT FOR RENAL DISEASES

Also Published As

Publication number Publication date
EP1331221A4 (en) 2005-11-23
US7589126B2 (en) 2009-09-15
WO2002028827A1 (fr) 2002-04-11
US20060116361A1 (en) 2006-06-01
ES2319504T3 (es) 2009-05-08
ATE420853T1 (de) 2009-01-15
CA2423631C (en) 2010-03-30
AU2001292331B2 (en) 2007-01-18
RU2273633C9 (ru) 2006-10-20
PL362530A1 (en) 2004-11-02
TWI303628B (en) 2008-12-01
US20070105829A1 (en) 2007-05-10
US7217832B2 (en) 2007-05-15
RU2273633C2 (ru) 2006-04-10
HK1061674A1 (en) 2004-09-30
EP1331221A1 (en) 2003-07-30
AU9233101A (en) 2002-04-15
CA2423631A1 (en) 2003-03-25
KR100625023B1 (ko) 2006-09-20
US7208524B2 (en) 2007-04-24
CN1468215A (zh) 2004-01-14
DE60137442D1 (de) 2009-03-05
NZ525114A (en) 2005-05-27
US20060205812A1 (en) 2006-09-14
MXPA03002975A (es) 2004-02-12
JP3967679B2 (ja) 2007-08-29
CN100439329C (zh) 2008-12-03
JPWO2002028827A1 (ja) 2004-02-12
EP1331221B1 (en) 2009-01-14
KR20030048424A (ko) 2003-06-19
PL206094B1 (pl) 2010-06-30

Similar Documents

Publication Publication Date Title
DK1213296T3 (da) Glucopyranosyloxpyrazolderivater, lægemidler indeholdende samme samt mellemprodukter til fremstilling heraf
BR0114424A (pt) Derivados de 5-amidino-2-hidróxi benzeno sulfonamida, composições farmacêuticas contendo os mesmos e intermediários para a sua preparação
MXPA03011638A (es) Nuevos derivados de 4-piperazinil indol con afinidad por el receptor 5-ht6.
EA200301306A1 (ru) Производные 1-фенилсульфонил-1,3-дигидро-2h-индол-2-она, их получение и их терапевтическое применение
BRPI0409109A (pt) novos compostos
FI950309A0 (fi) Proliiniamidijohdannaisia
NO20051209L (no) Pyrazolderivater, medisinske sammensetninger inneholdende slike, medisinsk anvendelse derav samt intermediater for samme
NO20081970L (no) Sulfonamidderivat med PGD2-reseptorantagonistaktivitet
NO20041112L (no) 1-Substituerte-1-aminometyl-cykloalkanderivater (=gabapentinanaloger), deres fremstilling og deres anvendelse ved behandiing av neurologiske lidelser
DK2314582T3 (da) Heterocykliske forbindelser som antivirusmidler
NO20074657L (no) Nitrogenholdige aromatiske ringforbindelser
ATE420859T1 (de) Azabicycloä3.1.0ühexylphenylderivate als modulatoren von dopamin-d3-rezeptoren
EA200801134A1 (ru) Замещенные бициклические пиримидоновые производные
BR9807132A (pt) Derivados de pirrolidina tendo atividade inibitória de fosfolipase a2
EP1396493A4 (en) HETEROCYCLIC COMPOUNDS
BR0308145A (pt) Composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto
ATE337318T1 (de) Spiroverbindungen und diese als wirkstoff enthaltende adhäsionsmolekülinhibitoren
BR0115454A (pt) Composto de 1-metilcarbapenem ou um sal ou derivado de éster deste farmaceuticamente aceitável, composição farmacêutica, e, uso de um composto ou de um sal ou derivado de éster deste farmaceuticamente aceitável
NO980333D0 (no) (R)-5-brom-N-(1-etyl-4-metylheksahydro-1H-1,4-diazepin-6-yl)-2-metoksy-6-metylamino-3-pyridinkarboksamid, fremgangsmåte ved fremstilling derav og farmasöytisk sammensetning inneholdende forbindelsen
ATE321550T1 (de) Medizinische zusammensetzungen zur unmittelbaren freisetzung bei oraler anwendung
NO323556B1 (no) Forbindelser, farmasoytiske preparater som omfatter forbindelsene, og anvendelse av forbindelsene ved fremstilling av antibakterielle medikamenter.
HUP0000966A2 (hu) Izoflavonszármazékok és ilyen vegyületeket hatóanyagként tartalmazó gyógyszerkészítmények
NO302234B1 (no) Cykloheksanderivat og farmasöytisk preparat omfattende dette

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2125 DE 27/09/2011.